Calcium channel blockers are well tolerated, and especially effective in treating low- renin hypertension. The initial bolus should be 0.25 mg/kg, intravenous (IV).īecause of its vasodilatory effects, diltiazem is useful for treating hypertension. Ītrial fibrillation or atrial flutter is another indication. Unstable angina ( preinfarction, crescendo) – diltiazem may be particularly effective if the underlying mechanism is vasospasm.įor supraventricular tachycardias ( PSVT), diltiazem appears to be as effective as verapamil in treating re-entrant supraventricular tachycardia.Variant angina – it is effective owing to its direct effects on coronary dilation.
Stable angina (exercise-induced) – diltiazem increases coronary blood flow and decreases myocardial oxygen consumption, secondary to decreased peripheral resistance, heart rate, and contractility.An extended release formulation is also available. In 2019, it was the 72nd most commonly prescribed medication in the United States, with more than 10 million prescriptions. ĭiltiazem was approved for medical use in the United States in 1982. It does this by blocking the entry of calcium into the cells of the heart and blood vessels. Additionally, it acts on the heart to prolong the period until it can beat again. ĭiltiazem works by relaxing the smooth muscle in the walls of arteries, resulting in them opening and allowing blood to flow more easily. It is unclear if use when breastfeeding is safe. Other severe side effects include an overly slow heart beat, heart failure, liver problems, and allergic reactions.
Ĭommon side effects include swelling, dizziness, headaches, and low blood pressure. When given by injection, effects typically begin within a few minutes and last a few hours.
It is taken by mouth or injection into a vein. It may also be used in hyperthyroidism if beta blockers cannot be used. Diltiazem, sold under the brand name Cardizem among others, is a calcium channel blocker medication used to treat high blood pressure, angina, and certain heart arrhythmias.
0 kommentar(er)
